COPENHAGEN, Jan 19 (Reuters) - The pandemic has blocked Novak Djokovic's march to tennis history, so the 34-year-old may be pinning his hopes on a cure for COVID to get his hands on another glorious grand slam before time runs out.
The Serbian superstar, who became a focus of the global vaccine debate over his failed attempt to enter Australia without being inoculated, holds a majority stake in a Danish biotech firm aiming to develop a treatment to counter COVID-19, the company's CEO told Reuters. read more
QuantBioRes boss Ivan Loncarevic, who described himself as an entrepreneur, said the tennis player's acquisition of the 80% stake was made in June 2020 but declined to say how much it was.
The company is developing a peptide, which inhibits the coronavirus from infecting the human cell, expects to launch clinical trials in Britain this summer, according to Loncarevic, who stressed the firm was working on a treatment, not a vaccine.
The CEO said the company had about a dozen researchers working in Denmark, Australia and Slovenia. According to the Danish company register, Djokovic and his wife Jelena own 40.8% and 39.2% of the company, respectively.
https://www.reuters.com/lifestyle/sports/djokovic-buys-80-danish-biotech-developing-covid-19-treatment-ceo-2022-01-19/
